(Total Views: 885)
Posted On: 12/09/2020 11:43:25 AM
Post# of 154117
“We have not applied yet for EUA correct?”
As far as investors know, an application for an EUA has not been filed for neither the M2M or S/C trial.
“So what are we looking at here with this positive share movement?”
The discovery of the ICD10 code for leronlimab has increased investor confidence that leronlimab will receive EUA once the S/C data is submitted (either at 75% or at full enrollment).
“Can we possibly get an EUA very quickly (a week)?”
With the hospitalizations and deaths continuing to rise, and expected to stay high through Feb (post Xmas and post New Years gatherings) the FDA needs a good therapeutic for the S/C population. If the S/C data trial demonstrates a statistically significant reduction in mortality, leronlimab could be approved quickly.
As far as investors know, an application for an EUA has not been filed for neither the M2M or S/C trial.
“So what are we looking at here with this positive share movement?”
The discovery of the ICD10 code for leronlimab has increased investor confidence that leronlimab will receive EUA once the S/C data is submitted (either at 75% or at full enrollment).
“Can we possibly get an EUA very quickly (a week)?”
With the hospitalizations and deaths continuing to rise, and expected to stay high through Feb (post Xmas and post New Years gatherings) the FDA needs a good therapeutic for the S/C population. If the S/C data trial demonstrates a statistically significant reduction in mortality, leronlimab could be approved quickly.
(8)
(0)
